Iurie Bulat

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park et al. · The Lancet Oncology · 2022 · 162 citations · Full text

Urology, Oncology, Metastatic Urothelial Carcinoma +7

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Tibor Csőszi, Marina Maglakelidze, Robert J. Hoyer et al. · Annals of Oncology · 2019 · 161 citations · Full text

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer

Ignacio Durán, Joan Carles, Iurie Bulat et al. · Clinical Pharmacokinetics · 2020 · 48 citations · Full text

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

Alessandro D. Santin, Ignace Vergote, Antonio González-Martı́n et al. · International Journal of Gynecological Cancer · 2022 · 36 citations · Full text

An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer

Bodine P.S. Belderbos, Ronald de Wit, Caly Chien et al. · Cancer Chemotherapy and Pharmacology · 2018 · 26 citations · Full text